From Molecule to Medication: Integrating Menin Inhibitors in Acute Myeloid Leukemia Practice

This activity was originally presented at the 2026 Oncology Pharmacists Connect Conference.

Program Description

Menin inhibitors represent a new treatment approach that targets key leukemia-driving pathways in specific acute myeloid leukemia (AML) subtypes. The role of menin inhibitors in AML requires oncology pharmacists to synthesize complex molecular and clinical data for treatment decisions. Effective management utilizes next-generation sequencing (NGS), European LeukemiaNet (ELN) risk stratification, and measurable residual disease (MRD) assessment, but inconsistent interpretation of genomic reports, prioritization of co-occurring mutations, and variable incorporation of MRD findings hinder this process. Oncology pharmacists often encounter challenges including limited access to mutation-prioritization frameworks, variability in molecular reporting, and rapid therapeutic advancements, and inconsistent guidance and institutional protocols further complicate supportive care implementation. The effective use of oral menin inhibitors requires coordinated workflows for timely therapy initiation. This session will review practical workflows and decision frameworks to integrate menin inhibitors into AML care pathways. Through real-world examples and interactive discussion, oncology pharmacists will explore common access and adherence barriers to oral menin inhibitors, including inpatient stocking challenges, coverage and cost issues, and financial toxicity, along with strategies to leverage patient assistance resources.

Target audience: Oncology pharmacists
Type of activity: Application
Release date: June 30, 2026
Expiration date: June 30, 2027
Learner level: Advanced, Intermediate
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze molecular and clinical patient profiles for evidence-based selection and sequencing of menin inhibitors within contemporary acute myeloid leukemia (AML) treatment pathways
• Employ risk-adapted monitoring and supportive care strategies to mitigate toxicities associated with menin inhibitor–based AML therapies
• Apply integrated access and workflow strategies for the timely initiation and continuity of oral menin inhibitor therapy across care settings

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-26-179-H01-P. The activity is available for CE credit through June 30, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Kyle Zacholski, PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose:

Other – Advisory Board: Jazz Pharmaceuticals

Bernard Marini, PharmD, BCOP, FHOPA, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: Jazz Pharmaceuticals, Servier Pharmaceuticals

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Kylie Ferrentino; Brianna Winters; and Chloe Taccetta.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com

Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms